Tevogen Bio expands oncology pipeline using ExacTcell™ tech for cancer treatments and COVID-19.

Tevogen Bio, a clinical-stage biotech firm, is expanding its pipeline to enhance oncology treatments and continuous care for cancer patients using their ExacTcell™ technology. They aim to develop off-the-shelf, genetically unmodified T cell therapies for cancers and infectious diseases, including COVID-19. The company's future growth depends on securing additional funding, navigating legal challenges, and facing market competition.

October 11, 2024
4 Articles